Bayer HealthCare, a subgroup of German conglomerate Bayer AG (BYR.L,BAYRY.PK,BAYZF.PK), said that the Phase III EINSTEIN-PE study, with nearly 5,000 patients, would be presented in the Late-Breaking Clinical Trials Session on Monday, March 26th, 2012, 08:00 - 09:30am CDT, at the American College of Cardiology's 61st Annual Scientific Sessions or ACC in Chicago, USA, by lead investigator Harry Buller, MD, Academic Medical Center, Amsterdam, the Netherlands.
The EINSTEIN-PE study compared an oral single-drug approach with rivaroxaban, intensified initial treatment with rivaroxaban 15 mg twice daily for three weeks followed by 20 mg once daily, with the current standard of care of initial subcutaneous enoxaparin followed by a VKA in patients with acute symptomatic pulmonary embolism or PE with or without symptomatic deep vein thrombosis or DVT.
This multinational, randomized, event-driven trial with blinded outcome assessment was sponsored by Bayer HealthCare and Janssen Research & Development, LLC.
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org